Holen Sie sich die Stockscreener-App
4.72
3.48%
-0.17
Handel nachbörslich:
4.87
0.15
+3.18%
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
Lipocine's LPCN 1148 Shows Breakthrough Results in Liver Disease Clinical Trial | LPCN Stock News - StockTitan
Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
When the Price of (LPCN) Talks, People Listen - Stock Traders Daily
Lipocine: Q3 Earnings Snapshot - CT Insider
Lipocine Inc. (LPCN) Quarterly 10-Q Report - Quartz
Lipocine Narrows Q3 Loss 67%, Eyes NDA Filing for Depression Drug After Positive Data | LPCN Stock News - StockTitan
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society Conference - Defense World
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - GuruFocus.com
Lipocine inks deal to bring TLANDO to South Korea - Investing.com
Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Morningstar
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com
Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1 - GuruFocus.com
Lipocine Announces Completion of Dosing in Pivotal Study of Post - GuruFocus.com
(LPCN) Trading Signals - Stock Traders Daily
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Bod - GuruFocus.com
Lipocine reports promising oral brexanolone study results By Investing.com - Investing.com Australia
Lipocine reports promising oral brexanolone study results - Investing.com India
Lipocine Enters Exclusive Supply And Distribution Agreement With Pharmalink - Contract Pharma
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PR Newswire
Lipocine signs supply and distribution agreement with Pharmalink for Tlando - Yahoo Finance
Lipocine partners with Pharmalink for GCC distribution of TLANDO - Investing.com
Lipocine partners with Pharmalink for GCC distribution of TLANDO By Investing.com - Investing.com Nigeria
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Citizentribune
Alliance Global Partners Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Upgraded to Buy at StockNews.com - Defense World
‘Lubber Pandhu also has strong emotions beyond cricket’ - DTNEXT
Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada
PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat
Liquidia Corp [LQDA] Investment Guide: What You Need to Know - Knox Daily
MediPharm Labs Corp. - Baystreet.ca
A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News
PLRX’s latest rating updates from top analysts. - Knox Daily
Labcorp Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat
Prudential PLC Sells 7,956 Shares of Laboratory Co. of America Holdings (NYSE:LH) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Research Analysts Set Expectations for Pliant Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PLRX) - Defense World
Lipocine Inc. filed SEC Form 8-K: Financial Statements and Exhibits - Quantisnow
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - Kilgore News Herald
Lipocine (NASDAQ:LPCN) Downgraded by StockNews.com to “Hold” - Defense World
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference – Company Announcement - Financial Times
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Sarcopenia Market to Grow Positively at a Paltry CAGR During - openPR
StockNews.com Lowers Lipocine (NASDAQ:LPCN) to Hold - Defense World
Lipocine (NASDAQ:LPCN) Raised to Buy at StockNews.com - Defense World
Lipocine: Q2 Earnings Snapshot - San Antonio Express-News
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 - Manchestertimes
LPCNLipocine Inc. Latest Stock News & Market Updates - StockTitan
Lipocine (NASDAQ:LPCN) Stock Price Passes Below Two Hundred Day Moving Average of $5.52 - Defense World
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):